Ormendes SA - First Published Clinical Trial In COVID-19 Suggests Role of Live Biotherapeutic Candidate in Seriously Ill Patients
Ormendes SA is proud to announce that one of its probiotic formulations has been used in a clinical study to supplement Covid-19 patients in addition to their standard care, the results of which have now been published in Frontiers in Medicine.
The fact that pneumonia and gastrointestinal symptoms are predominant clinical manifestations of COVID-19 disease can be explained by the fact that both organs express the ACE2 receptor, through which the SARS CoV-2 virus can enter cells. In the gut, where ACE2 receptors are abundantly present, coronavirus may multiply quickly. Hence the innovative idea of using a mix of bacterial strains (Sivomixx® 800) with proven biochemical, antiviral and immunological activities to raise the defenses of people infected by the SARS CoV-2 virus.
70 Covid-19 patients with lung involvement, for whom non-invasive oxygen therapy treatment was requested, were recruited in a study at the Policlinico Umberto I, Sapienza University, Roma, Italy. Patients were divided into two groups: one of 42 patients and the other one of 28. Both groups received a treatment based on hydroxychloroquine, antibiotics, and/or tocilizumab, whereas only the 28 patients in the second group concomitantly received Sivomixx® 800. Interestingly, nearly all patients treated with bacteriotherapy showed remission of diarrhea and improvement in fever, physical weakness and myalgia within few days. The patients receiving oral bacteriotherapy all survived the COVID-19 disease and none required invasive mechanical ventilation. Their estimated risk of developing respiratory failure was eight-fold lower compared to the group which was not supplemented with the formulation.
The study was published in Frontiers in Medicine (https://www.frontiersin.org/articles/10.3389/fmed.2020.00389/full ) . The data from this independent study are preliminary and will need to be confirmed by a more extensive trial.
SivoMixx® 800 is a food supplement containing different strains of lactic acid bacteria and bifidobacteria at a concentration of 800 billion CFU (Colony Forming Units) per sachet. It is not intended to treat, prevent, or cure any disease.
More information at www.sivomixx800.com
Ormendes is a biotechnology company focused on the development and commercialization of live biotherapeutic medicines (www.ormendes.ch ). Sivomixx® 800 is a probiotic food supplement (www.sivomixx800.com )
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-VELODYNE-LIDAR,-INC.29.9.2020 22:03:12 CEST | Press release
Velodyne Lidar, Inc. and Graf Industrial Corp. Announce Closing of Business Combination
NY-PHILIP-MORRIS-INTL29.9.2020 16:24:09 CEST | Press release
PMI to Address Equality & Transformation During Upcoming International Events
MD-SMITHS-DETECTION29.9.2020 16:02:18 CEST | Press release
SMITHS DETECTION INTRODUCES COMPACT X-RAY SCANNER FOR VERSATILE COMMERCIAL SECURITY APPLICATIONS
OR-AIRSHIP29.9.2020 15:02:13 CEST | Press release
Airship’s Data Study of Nearly 750 Million Individual App Users Finds Mobile App Engagement Rates Have Soared Under Lockdown
NY-CAT-ROCK-CAPITAL29.9.2020 15:00:12 CEST | Press release
Cat Rock Capital Issues Presentation on Just Eat Takeaway.com Merger with Grubhub
INVERSAGO-PHARMA-INC.29.9.2020 14:02:30 CEST | Press release
Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom